Tim Kutzkey Buys 2,562 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 2,562 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was acquired at an average cost of $20.00 per share, with a total value of $51,240.00. Following the completion of the acquisition, the director directly owned 1,007,090 shares of the company’s stock, valued at $20,141,800. The trade was a 0.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey acquired 18,052 shares of Surrozen stock. The shares were bought at an average cost of $19.60 per share, for a total transaction of $353,819.20.
• On Thursday, January 15th, Tim Kutzkey acquired 11,893 shares of Surrozen stock. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey bought 12,470 shares of Surrozen stock. The shares were bought at an average price of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were bought at an average cost of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The shares were acquired at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Down 10.1%

NASDAQ SRZN traded down $2.02 during trading hours on Tuesday, hitting $17.98. The company’s stock had a trading volume of 62,608 shares, compared to its average volume of 59,333. The stock has a fifty day moving average of $18.98 and a 200 day moving average of $14.13. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $24.94. The firm has a market capitalization of $154.09 million, a P/E ratio of -0.80 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last released its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Investors Weigh In On Surrozen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP acquired a new position in Surrozen in the 2nd quarter worth $1,252,000. Stempoint Capital LP raised its holdings in Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in shares of Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after buying an additional 47,468 shares in the last quarter. Finally, Acuta Capital Partners LLC increased its holdings in Surrozen by 5.0% during the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after buying an additional 8,415 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SRZN. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Surrozen currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.